"The Company has established a targeted plan to advance the clinical development of tecarfarin and, if approved, to commercialize it as a significant improvement for LVAD patients facing ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and ...

Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ...

The company is advancing its clinical development plan for rademikibart, with expectations to initiate parallel Phase 2 trials in the second quarter of 2025. The posters will feature findings on ...

today announced that the FDA has granted Adial’s request for an End of Phase 2 meeting to discuss Adial’s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with ...